Fractyl Health, Inc. Common Stock (GUTS)

USD 1.9

(-5.71%)

Market Cap (In USD)

91.38 Million

Revenue (In USD)

120 Thousand

Net Income (In USD)

-77.09 Million

Avg. Volume

370.54 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.74-14.5
PE
-
EPS
-
Beta Value
0.0
ISIN
US35168W1036
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Harith Rajagopalan M.D., Ph.D.
Employee Count
-
Website
https://fractyl.com
Ipo Date
Details
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.